| Bioactivity | Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis[1]. |
| Name | Idarucizumab |
| CAS | 1362509-93-0 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Finks SW, et al. Idarucizumab (Praxbind): The First Reversal Agent for a Direct Oral Anticoagulant. Am J Med. 2017 May;130(5):e195-e197. |